Teva Pharmaceutical Industries Limited (TEVA)

NYSE: TEVA · Real-Time Price · USD
17.52
+0.33 (1.92%)
At close: Jun 4, 2025, 4:00 PM
17.60
+0.08 (0.45%)
After-hours: Jun 4, 2025, 7:56 PM EDT
1.92%
Market Cap 20.09B
Revenue (ttm) 16.62B
Net Income (ttm) -1.29B
Shares Out 1.15B
EPS (ttm) -1.14
PE Ratio n/a
Forward PE 6.82
Dividend n/a
Ex-Dividend Date n/a
Volume 11,596,407
Open 17.19
Previous Close 17.19
Day's Range 17.14 - 17.66
52-Week Range 12.47 - 22.80
Beta 0.61
Analysts Strong Buy
Price Target 25.14 (+43.49%)
Earnings Date Jul 30, 2025

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 36,830
Stock Exchange NYSE
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, Teva Pharmaceutical's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price forecast is $25.14, which is an increase of 43.49% from the latest price.

Price Target
$25.14
(43.49% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announ...

1 day ago - GlobeNewsWire

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announ...

1 day ago - GlobeNewsWire

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results fro...

4 days ago - GlobeNewsWire

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the present...

4 days ago - GlobeNewsWire

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acce...

6 days ago - GlobeNewsWire

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celi...

8 days ago - GlobeNewsWire

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming ...

8 days ago - GlobeNewsWire

Why Is Teva Stock Trading Higher On Tuesday?

Teva Pharmaceutical Industries Ltd TEVA and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal lymphopoietin...

8 days ago - Benzinga

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

REHOVOT, Israel and WASHINGTON and TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”), a biotechnology c...

8 days ago - GlobeNewsWire

Why Investors Should Watch Teva Despite Regional Risks

Despite the lack of cautious enthusiasm from retail investors in Teva, it continues to beat consensus estimates by wide margins and has once again raised its 2025 financial guidance. I highlight Auste...

12 days ago - Seeking Alpha

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it is increasing the maximum tender amount of its tender offe...

13 days ago - GlobeNewsWire

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately...

15 days ago - GlobeNewsWire

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB...

15 days ago - GlobeNewsWire

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for...

16 days ago - GlobeNewsWire

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes...

16 days ago - GlobeNewsWire

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit ratin...

20 days ago - GlobeNewsWire

Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside

Teva's betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management's $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Re...

27 days ago - Seeking Alpha

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says

The drugmaker reported first-quarter earnings that beat expectations and raised its full-year guidance.

4 weeks ago - Barrons

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

Teva Pharmaceutical Industries Ltd TEVA stock is trading higher on Wednesday after the company's first-quarter 2025 financial results. Here are the details.

4 weeks ago - Benzinga

Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties

Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, any pharma shortages in the U.S., and much more.

4 weeks ago - CNBC Television

Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2025 Earnings Call May 7, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric A. Hughes - EVP...

4 weeks ago - Seeking Alpha

Teva Pharm first-quarter profit rise tops estimates

Teva Pharmaceutical Industries reported a slightly larger than expected rise in first-quarter profit, helped by strong sales gains in a trio of its branded drugs to treat migraines, Huntington's disea...

4 weeks ago - Reuters

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on Thursday, May 29, 2025 to di...

4 weeks ago - GlobeNewsWire

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaborat...

4 weeks ago - GlobeNewsWire

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. TEVA and Alvotech's ALVO Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biolog...

4 weeks ago - Benzinga